Ovarian Cancer Clinical Trials
There are 501 actively recruiting ovarian cancer clinical trials across 57 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.
Ovarian Cancer Trials at a Glance
501 actively recruiting trials for ovarian cancer are listed on ClinicalTrialsFinder across 6 cities in 57 countries. The largest study group is Phase 2 with 163 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running ovarian cancer studies include M.D. Anderson Cancer Center, AstraZeneca, and Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Browse ovarian cancer trials by phase
Top cities for ovarian cancer trials
Understanding Ovarian Cancer Clinical Trials
The approval of olaparib (Lynparza) in 2014, driven by clinical trial data, marked a turning point for ovarian cancer — offering the first PARP inhibitor as maintenance therapy that significantly extended progression-free survival in women with BRCA-mutated disease. Subsequent trials established niraparib and rucaparib as additional PARP inhibitor options, and bevacizumab (Avastin) demonstrated benefit when added to standard chemotherapy. Clinical trials continue to be critical for ovarian cancer because the disease is usually diagnosed at an advanced stage, and while initial treatment is often effective, most patients eventually experience a recurrence that requires new therapeutic strategies.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about Ovarian Cancer clinical trials
Yes. There are trials specifically designed for patients whose disease progressed on or after PARP inhibitor therapy. These trials may test new drug classes, combinations that work differently from PARP inhibitors, or next-generation PARP inhibitors designed to overcome resistance. Prior PARP inhibitor use does not exclude you from trial participation.
Yes, and this is one of the most active areas of ovarian cancer research. Platinum-resistant disease, where cancer returns within six months of completing platinum-based chemotherapy, has limited standard options. Multiple trials are testing antibody-drug conjugates, bispecific antibodies, and novel immunotherapy approaches specifically for this population.
No. While some trials specifically enroll patients with BRCA mutations, many ovarian cancer trials are open to all patients regardless of BRCA status. Some trials select patients based on other biomarkers like HRD status or folate receptor expression. There are trials available for virtually every molecular profile.
It depends on the trial. Most drug-based clinical trials do not require additional surgery, though some may require a tumor biopsy for biomarker testing. Surgical trials, which study techniques like HIPEC or optimal debulking approaches, will involve operative procedures. The informed consent document will clearly outline any surgical requirements.
Most ovarian cancer trials include regular CA-125 monitoring as part of the study protocol, often at every visit or every treatment cycle. However, treatment decisions within trials are typically based on imaging scans (CT or PET-CT) rather than CA-125 alone, since CA-125 levels can fluctuate for reasons unrelated to disease status.
Showing 1–20 of 501 trials